Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Rani Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105
Details : Under the agreement, Celltrion will exclusively supply to Rani the adalimumab biosimilar drug substance (CT-P17) required for the development of RT-105, an oral capsule containing a TNF-α inhibitor antibody being developed for the treatment of psoriatic...
Product Name : Yuflyma
Product Type : Antibody
Upfront Cash : Undisclosed
May 06, 2023
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Rani Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : IMVT-1402
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Immunovant
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402). In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL c...
Product Name : IMVT-1402
Product Type : Antibody
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : IMVT-1402
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Immunovant
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : SK Chemicals
Deal Size : Inapplicable
Deal Type : Inapplicable
Standigm and SK Chemicals Repurpose FDA-Approved Drug into Rheumatoid Arthritis Candidate
Details : The compound in the patent was discovered by Standigm Insight™. In a mouse model, it showed comparable or better improvements in its rheumatoid arthritis disease activity score than reference drugs such as methotrexate and hydroxychloroquine.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : SK Chemicals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ILB-202
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States
Details : This latest patent is integral to the Company's EXPLOR® platform technology as well as the Exo-Target® products, as the patent covers not only EXPLOR® technology but also its application for various therapeutic cargo proteins developed by ILIAS for lo...
Product Name : ILB-202
Product Type : Protein
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : ILB-202
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable